The present invention relates to a method of improving flock uniformity and/or meat quality of a monogastric animal comprising administering to the animal a composition, an animal feed or an animal feed additive comprising one or more microbial muramidases.

The present invention relates to a pharmaceutical composition containing a combination of vitamins, specific salts of calcium, magnesium, and iron, probiotics and prebiotics, which prevents the occurrence of adverse effects associated with long-term use of proton-pump inhibitors (PPIs). This effect is achieved by restoring all nutrient deficiencies and rectifying the intestinal flora imbalance caused by this type of drugs, particularly in patients with gastroesophageal reflux disease and Zollinger-Ellison syndrome.

Compositions for oral administration and processes of preparing the same are described. In particular, compositions in the form of bilayer tablets including B vitamins for modified delivery are described. The bilayer multi-B vitamin tablets offer immediate release of a first set of B vitamins, such as riboflavin (B2) and cyanocobalamin (B12) followed by controlled release of a second set of B vitamins, such as folic acid, biotin, niacinamide (B3), pyridoxine (B6), pantothenic acid (B5) and thiamine (B1).

An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.

This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.

Disclosed are a composition including (6S)-5-methyl tetrahydrofolic acid or a salt thereof, and preparation and use thereof. In the composition, the content of (6S)-5-methyl tetrahydrofolic acid or the salt thereof is not less than 98.0%, the content of a related impurity JK12A is not greater than 0.1%, and 5-methyl tetrahydropterioic acid is not detectable.

The present invention relates to the use of transgenic plants for the expression of vitamin B12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin B12 binding proteins. The present invention also relates to the use of recombinant vitamin B12 binding proteins from plants in analytical tests and treatment of vitamin B12 deficiency. Also disclosed is a method for purification of recombinant vitamin B12 binding proteins.

The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.

The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.

##STR00001##

The present disclosure relates generally to conjugates and their uses and production. More particularly, it concerns conjugates comprising an A44 or K39 gingipain adhesion peptide, or fragment thereof (e.g., an A44/K39 peptide portion) covalently attached to a heterologous agent that is capable of entering a cell by endocytosis and translocating to mitochondria.